Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion

Trial Profile

Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Retinal oedema; Retinal vein occlusion
  • Focus Registrational; Therapeutic Use
  • Acronyms RVO3
  • Sponsors Allergan
  • Most Recent Events

    • 01 Jan 2018 Primary endpoint of Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity in the Study Eye has been met, according to results published in the Graefes Archive for Clinical and Experimental Ophthalmology.
    • 01 Jan 2018 Results published in the Graefes Archive for Clinical and Experimental Ophthalmology
    • 21 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top